Cambridge Investment Research Advisors’s Aquestive Therapeutics AQST Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$118K	Hold	28,317	–	–	﹤0.01%	3915
2026 Q1	$118K	Buy	28,317 +4,450	+19%	+$18.1K	﹤0.01%	3772
2025 Q4	$154K	Buy	23,867 +5,511	+30%	+$34.3K	﹤0.01%	3629
2025 Q3	$103K	Buy	18,356 +550	+3%	+$2.38K	﹤0.01%	3589
2025 Q2	$59K	Buy	17,806 +6,503	+58%	+$18.7K	﹤0.01%	3523
2025 Q1	$33K	Buy	+11,303	New	+$34.2K	﹤0.01%	3430

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Cambridge Investment Research Advisors's AQST Position: Q2 2026 in Review

Cambridge Investment Research Advisors held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 28,317 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #3915.

Cambridge Investment Research Advisors first reported a position in AQST in Q1 2025 and has held it in 6 quarters since. The position peaked at $154K in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Cambridge Investment Research Advisors held 28,317 shares of Aquestive Therapeutics worth $118K as of Q2 2026.
Cambridge Investment Research Advisors left its Aquestive Therapeutics share count unchanged in Q2 2026.
Aquestive Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3915 holding.
Cambridge Investment Research Advisors first reported a position in Aquestive Therapeutics in Q1 2025 and has held it in 6 quarters since.
Cambridge Investment Research Advisors's Aquestive Therapeutics position peaked at $154K in Q4 2025.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.